XERS — Xeris Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$8.43
-$0.01 (-0.12%)
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on NASDAQ. It is led by John P. Shannon, based in 1375 West Fulton Street, Chicago, IL, United States, 60607, with about 394 employees. Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Latest reported XERS revenue for 2025-09-30 was $74.4M. Net income was $621.0K. Revenue was up 4.0% from 2025-06-30 to 2025-09-30. XERS currently screens at market cap $760.7M.
Use this XERS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the XERS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the XERS SEC filings page. Lician reads the product cache first so this HTML stays unique to Xeris Pharmaceuticals Inc even when a live quote feed is slow.
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS Key Statistics
Market Cap
$760.74M
Volume
94,510
Previous Close
$8.74
Day Range
$8.77 – $8.94
EPS
-$0.37
Revenue
$203.07M
Net Income
-$54.84M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+23.9%
Profit Margin
-27.0%
Employees
394
XERS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $203.07M | $163.91M | $110.25M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$54.84M | -$62.26M | -$94.66M |
| EPS (Diluted) | -$0.37 | -$0.45 | -$0.70 |
Total Assets
$323.06M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$71.62M
Operating Cash Flow
-$36.98M
Free Cash Flow
$0.00
Xeris Pharmaceuticals Inc Company Information
- CEO & Director
- John P. Shannon
- Headquarters
- 1375 West Fulton Street, Chicago, IL, United States, 60607
- Website
- www.xerispharma.com
- Phone
- 844 445 5704
- IPO / Founded
- 2018-06-21
- Sector
- Healthcare
- Industry
- Biotechnology